CN116850351A - 一种具有较强抗菌作用的粘弹剂 - Google Patents
一种具有较强抗菌作用的粘弹剂 Download PDFInfo
- Publication number
- CN116850351A CN116850351A CN202310613870.5A CN202310613870A CN116850351A CN 116850351 A CN116850351 A CN 116850351A CN 202310613870 A CN202310613870 A CN 202310613870A CN 116850351 A CN116850351 A CN 116850351A
- Authority
- CN
- China
- Prior art keywords
- viscoelastic
- viscoelastic agent
- silver
- strong antibacterial
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 40
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 78
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 55
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 35
- 239000004327 boric acid Substances 0.000 claims abstract description 26
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 22
- 230000003204 osmotic effect Effects 0.000 claims abstract description 21
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229920000153 Povidone-iodine Polymers 0.000 claims abstract description 19
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims abstract description 19
- 229960003957 dexamethasone Drugs 0.000 claims abstract description 19
- 229960001621 povidone-iodine Drugs 0.000 claims abstract description 19
- 229910021538 borax Inorganic materials 0.000 claims abstract description 15
- 239000004328 sodium tetraborate Substances 0.000 claims abstract description 15
- 235000010339 sodium tetraborate Nutrition 0.000 claims abstract description 15
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims abstract description 14
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 14
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 14
- 239000011780 sodium chloride Substances 0.000 claims abstract description 14
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 14
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical group [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 14
- 239000003190 viscoelastic substance Substances 0.000 claims abstract description 14
- 229940006076 viscoelastic substance Drugs 0.000 claims abstract description 14
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000006174 pH buffer Substances 0.000 claims abstract description 8
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 7
- 229920001661 Chitosan Polymers 0.000 claims abstract description 7
- 239000001110 calcium chloride Substances 0.000 claims abstract description 7
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 7
- 239000000017 hydrogel Substances 0.000 claims abstract description 7
- 229910001629 magnesium chloride Inorganic materials 0.000 claims abstract description 7
- 239000002504 physiological saline solution Substances 0.000 claims abstract description 7
- 229920001184 polypeptide Polymers 0.000 claims abstract description 7
- 239000001103 potassium chloride Substances 0.000 claims abstract description 7
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 7
- 229910052709 silver Inorganic materials 0.000 claims description 30
- 239000004332 silver Substances 0.000 claims description 30
- 229940009188 silver Drugs 0.000 claims description 30
- 239000002245 particle Substances 0.000 claims description 23
- 230000001954 sterilising effect Effects 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 17
- 238000004659 sterilization and disinfection Methods 0.000 claims description 16
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 6
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 6
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 abstract description 10
- 230000001050 lubricating effect Effects 0.000 abstract description 3
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 230000006870 function Effects 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 208000002177 Cataract Diseases 0.000 description 7
- 241000233866 Fungi Species 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 6
- 206010059866 Drug resistance Diseases 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 241001052560 Thallis Species 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 244000052616 bacterial pathogen Species 0.000 description 5
- 244000000010 microbial pathogen Species 0.000 description 5
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 235000010338 boric acid Nutrition 0.000 description 4
- 125000005619 boric acid group Chemical group 0.000 description 4
- 235000011167 hydrochloric acid Nutrition 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000006179 pH buffering agent Substances 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 229960003600 silver sulfadiazine Drugs 0.000 description 4
- 235000011121 sodium hydroxide Nutrition 0.000 description 4
- 208000010412 Glaucoma Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 239000000645 desinfectant Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002406 microsurgery Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 229910001961 silver nitrate Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 241001420836 Ophthalmitis Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010039705 Scleritis Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 210000000399 corneal endothelial cell Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 201000004614 iritis Diseases 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 208000001491 myopia Diseases 0.000 description 2
- 230000004379 myopia Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000008557 oxygen metabolism Effects 0.000 description 2
- 208000010403 panophthalmitis Diseases 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 2
- 229960004306 sulfadiazine Drugs 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 108010082714 Silver Proteins Proteins 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002016 colloidosmotic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012213 gelatinous substance Substances 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 230000001937 non-anti-biotic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/028—Other inorganic materials not covered by A61L31/022 - A61L31/026
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/145—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/202—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with halogen atoms, e.g. triclosan, povidone-iodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/43—Hormones, e.g. dexamethasone
Abstract
本具有较强抗菌作用的粘弹剂包括粘弹性物质、基于硼酸和/或硼酸盐的pH缓冲剂、渗透压调节剂、纳米银、地塞米松、聚维酮碘和生理盐水;粘弹性物质为透明质酸钠、智能型水凝胶、医用几丁糖和多肽;渗透压调节剂为氯化钠、氯化钾、氯化镁和氯化钙。组分为:透明质酸钠:1.5%‑2.5%w/v;硼酸:0.7%‑0.85%w/v;硼砂:0.04%‑0.07%w/v;氯化钠:0.3%‑0.7%w/v;纳米银:0.001%‑0.3%w/v;地塞米松:0.01%‑0.1%w/v;聚维酮碘:0.01%‑0.5%w/v;余量为生理盐水。其在眼科手术中起到填充支撑润滑作用,对接触到部位起到抗菌消炎效果。
Description
技术领域
本发明涉及医用生物材料领域,具体涉及一种具有较强抗菌作用的粘弹剂。
背景技术
粘弹剂是一种高分子材料构成,具有一定粘弹性、无毒、无抗原性的透明大分子凝胶状物质,粘弹剂的化学性质表现为惰性、电解质平衡、与角膜或房水有着相同的晶状体渗透压和胶体渗透压、有pH缓冲体系的水溶液,还具有高纯度、无微粒、透明、易于注入和清除,并且在眼组织中可物性去除。所以要求粘弹剂必须是无菌、无毒、无热原、无炎性反应和无免疫原性,不干扰与其接触的细胞的正常代谢,在室温下有一个相当长的保存时期。
目前,粘弹剂已广泛应用于白内障手术、人工晶状体植入、穿透性角膜移植术、青光眼手术以及眼外伤等显微手术中。现今有效治疗白内障的方法只有手术,经过多年的发展,超声乳化白内障摘除技术合并人工晶状体植入术已经成为最常用的白内障手术方式。为了提高手术质量,创造手术空间,稳定眼压,减少手术操作对角膜内皮细胞的损伤等,粘弹剂是白内障手术必要的辅助材料,它具有一定的粘弹性和无毒、无抗原等生物安全性,在眼科手术过程中起到一定的填充、支撑、润滑和保护的作用。粘弹剂也是具有维持前房深度,利于手术操作,保护角膜内皮细胞,防止术中出血和分离粘连等具有保护功能的高分子材料,显著提高了许多眼内手术的质量。其主要功能是临床医生作为眼科显微手术的手术垫,起临时支撑手术空间用,使组织免于受手术器械的机械损伤,方便手术顺利实施。
眼科手术粘弹剂的物理特性是由其分子链的长度和链内链间分子的相互作用特性所决定的,由于高分子材料结构不同,所以理化性质也不同,医生了解了这些材料的特性后,会根据手术要求选择某种合适的粘弹剂。目前临床上已有各种不同品牌的粘弹剂,分为不同的规格、不同品种、不同原料的粘弹剂,由于临床上使用的粘弹剂绝大部分为单一物质组成,鉴于不同眼科手术对粘弹剂要求也不同,甚至手术的不同阶段对粘弹剂要求也不同,所以人们一直在不断地探索研制新型粘弹剂,以适应不同眼内显微手术中的需求。因此,至今还没有一种粘弹剂能够在患者眼内具有抗菌作用。
有鉴于此,本发明人针对现有技术中的上述缺陷深入研究,遂有本案产生。
发明内容
为解决上述技术问题,我们提出了一种具有较强抗菌作用的粘弹剂,不仅在眼科手术过程中起到一定的填充、支撑、润滑和保护的作用,还能够对周围接触到的部位起到抗菌消炎的效果。
为达到上述目的,本发明的技术方案如下:
一种具有较强抗菌作用的粘弹剂,包括粘弹性物质、基于硼酸和/或硼酸盐的pH缓冲剂、渗透压调节剂、纳米银、地塞米松、聚维酮碘和生理盐水;所述粘弹性物质选自透明质酸钠、智能型水凝胶、医用几丁糖、多肽、硫酸软骨素和羧甲基纤维素钠;所述渗透压调节剂选自氯化钠、氯化钾、氯化镁和氯化钙。
上述的具有较强抗菌作用的粘弹剂由下述组分组成:
透明质酸钠:1.5%-2.5%w/v;
硼酸:0.7%-0.85%w/v;
硼砂:0.04%-0.07%w/v;
氯化钠:0.3%-0.7%w/v;
纳米银:0.0001%-0.5%w/v;
地塞米松:0.001%-0.2%w/v;
聚维酮碘:0.001%-1%w/v;
余量为生理盐水。
优选的,所述纳米银为将粒径做到纳米级的金属银单质,且银单质的粒径为25-50纳米。
优选的,所述纳米银的含量为0.001%-0.01%w/v。
优选的,所述地塞米松的含量为0.02%-0.2%w/v。
优选的,所述聚维酮碘的含量为0.02%-0.2%w/v。
优选的,所述粘弹剂在0.25s-1剪切速率下的灭菌后粘度为100-300Pa.s。
优选的,所述粘弹剂的pH范围为6.8-7.5。
优选的,所述粘弹剂的渗透压范围为280-340mOsmol/kg。
通过上述技术方案,本发明通过在粘弹剂中添加有纳米银、地塞米松和聚维酮碘,纳米银颗粒具有超强的渗透性,纳米银颗粒与病原菌的细胞壁/膜结合后,能直接进入菌体、迅速与氧代谢酶的巯基(-SH)结合,使酶失活,阻断呼吸代谢使其窒息而死。独特的杀菌机理,使得纳米银颗粒在低浓度就可迅速杀死致病菌。对普通细菌、顽固细菌、耐药细菌以及真菌引起的较深处的组织感染均有良好的杀菌作用。同时纳米银可促进伤口愈合,促进受损细胞的修复与再生,去腐生肌,抗菌消炎改善创伤周围组织的微循环,有效地激活并促进组织细胞的生长,加速伤口的愈合,减少疤痕的生成。能够对数百种致病微生物都有强烈的抑制和杀灭作用,而且不会产生耐药性。地塞米松可用于各种原因引起的眼部炎症,包括角膜炎、巩膜炎、虹膜炎、疱疹性眼炎、交感性眼炎、白内障摘除并植入人工晶体后引起的术后眼内炎症、青光眼手术、角膜移植手术、治疗近视手术等。聚维酮碘为广谱的强力杀菌消毒剂,可直接使菌体内的蛋白质变性、沉淀,致使病原微生物死亡,从而高效消毒和杀菌,能杀死病毒、细菌、芽孢、真菌、原虫等,且毒性低,其作用持久,使用安全、简便。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
下面结合实施例和具体实施方式对本发明作进一步详细的说明。
实施例1.
一种具有较强抗菌作用的粘弹剂,包括粘弹性物质、基于硼酸和/或硼酸盐的pH缓冲剂、渗透压调节剂、纳米银、地塞米松、聚维酮碘和生理盐水;所述粘弹性物质选自透明质酸钠、智能型水凝胶、医用几丁糖、多肽、硫酸软骨素和羧甲基纤维素钠;所述基于硼酸和/或硼酸盐的pH缓冲剂选自硼酸和/或硼砂,硼酸和氢氧化钠,硼砂和盐酸;所述渗透压调节剂选自氯化钠、氯化钾、氯化镁和氯化钙;所述纳米银为将粒径做到纳米级的金属银单质,且银单质的粒径为25纳米。
本例中的具有较强抗菌作用的粘弹剂由下述组分组成:
透明质酸钠:1.5%w/v;
硼酸:0.7%w/v;
硼砂:0.04%w/v;
氯化钠:0.3%w/v;
纳米银:0.02%w/v;
地塞米松:0.02%w/v;
聚维酮碘:0.15%w/v;
余量为生理盐水。
所述粘弹剂在0.25s-1剪切速率下的灭菌后粘度为100Pa.s。所述粘弹剂的pH范围为6.8。所述粘弹剂的渗透压范围为280mOsmol/kg。
实施例2.
一种具有较强抗菌作用的粘弹剂,包括粘弹性物质、基于硼酸和/或硼酸盐的pH缓冲剂、渗透压调节剂、纳米银、地塞米松、聚维酮碘和生理盐水;所述粘弹性物质选自透明质酸钠、智能型水凝胶、医用几丁糖、多肽、硫酸软骨素和羧甲基纤维素钠;所述基于硼酸和/或硼酸盐的pH缓冲剂选自硼酸和/或硼砂,硼酸和氢氧化钠,硼砂和盐酸;所述渗透压调节剂选自氯化钠、氯化钾、氯化镁和氯化钙;所述纳米银为将粒径做到纳米级的金属银单质,且银单质的粒径为25纳米。
本例中的具有较强抗菌作用的粘弹剂由下述组分组成:
透明质酸钠:1.8%%w/v;
硼酸:0.75%w/v;
硼砂:0.05%w/v;
氯化钠:0.4%w/v;
纳米银:0.01%w/v;
地塞米松:0.1%w/v;
聚维酮碘:0.1%w/v;
余量为生理盐水。
所述粘弹剂在0.25s-1剪切速率下的灭菌后粘度为150Pa.s。所述粘弹剂的pH范围为7.0。所述粘弹剂的渗透压范围为290mOsmol/kg。
实施例3.
一种具有较强抗菌作用的粘弹剂,包括粘弹性物质、基于硼酸和/或硼酸盐的pH缓冲剂、渗透压调节剂、纳米银、地塞米松、聚维酮碘和生理盐水;所述粘弹性物质选自透明质酸钠、智能型水凝胶、医用几丁糖、多肽、硫酸软骨素和羧甲基纤维素钠;所述基于硼酸和/或硼酸盐的pH缓冲剂选自硼酸和/或硼砂,硼酸和氢氧化钠,硼砂和盐酸;所述渗透压调节剂选自氯化钠、氯化钾、氯化镁和氯化钙;所述纳米银为将粒径做到纳米级的金属银单质,且银单质的粒径为30纳米。
本例中的具有较强抗菌作用的粘弹剂由下述组分组成:
透明质酸钠:2.0%w/v;
硼酸:0.78w/v;
硼砂:0.055%w/v;
氯化钠:0.5%w/v;
纳米银:0.001%w/v;
地塞米松:0.15w/v;
聚维酮碘:0.02%w/v;
余量为生理盐水。
所述粘弹剂在0.25s-1剪切速率下的灭菌后粘度为200Pa.s。所述粘弹剂的pH范围为7.1。所述粘弹剂的渗透压范围为300mOsmol/kg。
实施例4.
一种具有较强抗菌作用的粘弹剂,包括粘弹性物质、基于硼酸和/或硼酸盐的pH缓冲剂、渗透压调节剂、纳米银、地塞米松、聚维酮碘和生理盐水;所述粘弹性物质选自透明质酸钠、智能型水凝胶、医用几丁糖、多肽、硫酸软骨素和羧甲基纤维素钠;所述基于硼酸和/或硼酸盐的pH缓冲剂选自硼酸和/或硼砂,硼酸和氢氧化钠,硼砂和盐酸;所述渗透压调节剂选自氯化钠、氯化钾、氯化镁和氯化钙;所述纳米银为将粒径做到纳米级的金属银单质,且银单质的粒径为35纳米。
本例中的具有较强抗菌作用的粘弹剂由下述组分组成:
透明质酸钠:2.2%w/v;
硼酸:0.80%w/v;
硼砂:0.06%%w/v;
氯化钠:0.55%w/v;
纳米银:0.01%w/v;
地塞米松:0.15%w/v;
聚维酮碘:0.15%w/v;
余量为生理盐水。
所述粘弹剂在0.25s-1剪切速率下的灭菌后粘度为230Pa.s。所述粘弹剂的pH范围为7.2。所述粘弹剂的渗透压范围为315mOsmol/kg。
上述实施例中均采用了纳米银的成分,总所周知,纳米(nm)是继微米之后的目前最小的一种计量单位,1纳米为百万分之一毫米,即毫微米,也就是十亿分之一米。纳米银,是利用前沿纳米技术将银纳米化,纳米技术出现,使银在纳米状态下的杀菌能力产生了质的飞跃,极少的纳米银可产生强大的杀菌作用,可在数分钟内杀死数百种细菌,广谱杀菌且无任何的耐药性,能够促进伤口的愈合、细胞的生长及受损细胞的修复,无任何毒性反应,对皮肤也未发现任何刺激反应,这给广泛应用纳米银来抗菌开辟了广阔的前景,是最新一代的天然抗菌剂,具体来说纳米银杀菌以下特点:
广谱抗菌
纳米银颗粒直接进入菌体与氧代谢酶(-SH)结合,使菌体窒息而死的独特作用机制,可杀死与其接触的大多数细菌、真菌、霉菌、孢子等微生物。经国内八大权威机构研究发现:其对耐药病原菌如耐药大肠杆菌、耐药金葡萄球菌、耐药绿脓杆菌、化脓链球菌、耐药肠球菌,厌氧菌等有全面的抗菌活性;对烧烫伤及创伤表面常见的细菌如金黄色葡萄球菌、大肠杆菌、绿脓杆菌、白色念珠菌及其它G+、G-性致病菌都有杀菌作用;对沙眼衣原体、引起性传播性疾病的淋球菌也有强大的杀菌作用。
一种抗生素能杀灭大约6种病原体,而纳米银可杀灭数百种致病微生物。杀灭细菌、真菌、滴虫、支/衣原体、淋球菌,杀菌作用强,对抗菌素耐药菌有同样杀灭作用。
强效杀菌
据研究发现,Ag可在数分钟内杀死650多种细菌。纳米银颗粒与病原菌的细胞壁/膜结合后,能直接进入菌体、迅速与氧代谢酶的巯基(-SH)结合,使酶失活,阻断呼吸代谢使其窒息而死。独特的杀菌机理,使得纳米银颗粒在低浓度就可迅速杀死致病菌。
渗透性强
纳米银颗粒具有超强的渗透性,可迅速渗入皮下2mm杀菌,对普通细菌、顽固细菌、耐药细菌以及真菌引起的较深处的组织感染均有良好的杀菌作用。
修复再生
纳米银可促进伤口愈合,促进受损细胞的修复与再生,去腐生肌,抗菌消炎改善创伤周围组织的微循环,有效地激活并促进组织细胞的生长,加速伤口的愈合,减少疤痕的生成。
抗菌持久
纳米银颗粒利用专利技术生产,外有一层保护膜,在人体内能逐渐释放,所以抗菌效果。
无耐药性
纳米银属于非抗菌素杀菌剂:纳米银能杀灭各种致病微生物,比抗菌素更强,10nm大小的纳米银颗粒独特抗菌机理可迅速直接杀死细菌,使其丧失繁殖能力,因此,无法生产耐药性的下一代,能有效避免因耐药性而导致反复发作久治不愈。
银在现代医学上的应用:
早在1884年,德国产科医生F.Crede(克劳德),把浓度为1%的硝酸银溶液滴入新生儿眼中,预防新生儿结膜炎导致的失明,使婴儿失明的发生率从10%降到了0.2%,直到今天,许多国家仍在使用Crede预防法。另外,早在1893年,C.Von Nageli(纳格列)经过系统的研究,首次报道了金属(尤其是银)对细菌和其它低等生物的致死效应,使银有可能成为一种消毒剂。从此,对银的利用进入了现代时期。
因此,目前银以多种形式应用于现代医学,包括:
(1)银盐:0.5%的硝酸银是治疗烧伤和创伤的标准溶液;10-20%的硝酸银溶液涂抹,可以用于治疗宫颈糜烂。
(2)磺胺嘧啶银:哥伦比亚大学Charles L.Fox(弗克斯)教授将银和磺胺嘧啶化合,产生的磺胺嘧啶银,其活性比单独的磺胺活性至少强50倍。1968年,磺胺嘧啶银(Sulfadiazine Silver)引入市场,由于它对各种细菌、真菌都有高效的杀灭作用,能够自然、无痛地对伤口部位进行完全修复,不用植皮,已成为治疗外伤(如烧伤)的重要药物。目前已被列入国家基本医疗保险药品目录。
(3)胶体银或银蛋白:是有效的局部抗感染物质,胶态银可以用于妇科消毒杀菌。
(4)镀银物质:银研究的创始人,A.B.Flick(弗莱克)博士开发了一种银的产品,即在绷带上涂一层银,作为敷料使用。受他的启发,人们利用银的抗菌性,陆续开发了镀银缝合线、镀银导管等。目前美国已有十几种含银产品,作为医疗器械获得了FDA的上市批准,包括银敷料、银凝胶、银粉末和其他类型的医疗产品。
上述实施例中也均采用了地塞米松作为成分之一,地塞米松可用于各种原因引起的眼部炎症,包括角膜炎、巩膜炎、虹膜炎、疱疹性眼炎、交感性眼炎、白内障摘除并植入人工晶体后引起的术后眼内炎症、青光眼手术、角膜移植手术、治疗近视手术等。
同样作为本具有较强抗菌作用的粘弹剂配方中的聚维酮碘为广谱的强力杀菌消毒剂,可直接使菌体内的蛋白质变性、沉淀,致使病原微生物死亡,从而高效消毒和杀菌,能杀死病毒、细菌、芽孢、真菌、原虫等,且毒性低,其作用持久,使用安全、简便。
以上所述的仅是本发明的一种具有较强抗菌作用的粘弹剂优选实施方式,应当指出,对于本领域的普通技术人员来说,在不脱离本发明创造构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。
Claims (9)
1.一种具有较强抗菌作用的粘弹剂,其特征在于,包括粘弹性物质、基于硼酸和/或硼酸盐的pH缓冲剂、渗透压调节剂、纳米银、地塞米松、聚维酮碘和生理盐水;所述粘弹性物质选自透明质酸钠、智能型水凝胶、医用几丁糖、多肽、硫酸软骨素和羧甲基纤维素钠;所述渗透压调节剂选自氯化钠、氯化钾、氯化镁和氯化钙。
2.根据权利要求1所述的一种具有较强抗菌作用的粘弹剂,其特征在于,其由下述组分组成:
透明质酸钠:1.5%-2.5%w/v;
硼酸:0.7%-0.85%w/v;
硼砂:0.04%-0.07%w/v;
氯化钠:0.3%-0.7%w/v;
纳米银:0.0001%-0.5%w/v;
地塞米松:0.001%-0.2%w/v;
聚维酮碘:0.001%-1%w/v;
余量为生理盐水。
3.根据权利要求2所述的一种具有较强抗菌作用的粘弹剂,其特征在于,所述纳米银为将粒径做到纳米级的金属银单质,且银单质的粒径为25-50纳米。
4.根据权利要求3所述的一种具有较强抗菌作用的粘弹剂,其特征在于,所述纳米银的含量为0.001%-0.01%w/v。
5.根据权利要求4所述的一种具有较强抗菌作用的粘弹剂,其特征在于,所述地塞米松的含量为0.02%-0.2%w/v。
6.根据权利要求5所述的一种具有较强抗菌作用的粘弹剂,其特征在于,所述聚维酮碘的含量为0.02%-0.2%w/v。
7.根据权利要求6所述的一种具有较强抗菌作用的粘弹剂,其特征在于,所述粘弹剂在0.25s-1剪切速率下的灭菌后粘度为100-300Pa.s。
8.根据权利要求7所述的一种具有较强抗菌作用的粘弹剂,其特征在于,所述粘弹剂的pH范围为6.8-7.5。
9.根据权利要求8所述的一种具有较强抗菌作用的粘弹剂,其特征在于,所述粘弹剂的渗透压范围为280-340mOsmol/kg。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310613870.5A CN116850351A (zh) | 2023-05-29 | 2023-05-29 | 一种具有较强抗菌作用的粘弹剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310613870.5A CN116850351A (zh) | 2023-05-29 | 2023-05-29 | 一种具有较强抗菌作用的粘弹剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116850351A true CN116850351A (zh) | 2023-10-10 |
Family
ID=88224065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310613870.5A Pending CN116850351A (zh) | 2023-05-29 | 2023-05-29 | 一种具有较强抗菌作用的粘弹剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116850351A (zh) |
-
2023
- 2023-05-29 CN CN202310613870.5A patent/CN116850351A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Percival et al. | Antiseptics for treating infected wounds: efficacy on biofilms and effect of pH | |
JP6348892B2 (ja) | 抗菌組成物 | |
Massarelli et al. | Polyvinyl alcohol/chitosan wound dressings loaded with antiseptics | |
ES2363674T3 (es) | Líquido que comprende trehalosa para su uso en la prevención de la adhesión de tejidos. | |
KR101155884B1 (ko) | 하이드로카르빌 설톤 화합물에 의해 화학적으로 변형된폴리아미노사카라이드 | |
CN105012993B (zh) | 一种阳离子医用生物胶抗菌敷料及其制备方法 | |
CN108187132A (zh) | 一种聚维酮碘水凝胶抗菌敷料及其制备方法 | |
JP6491647B2 (ja) | キトサンペースト創傷手当て材 | |
JP7020700B2 (ja) | 抗菌組成物 | |
CN105079858B (zh) | 一种伤口杀菌修复液体敷料及其制法 | |
HU225329B1 (en) | Use of zinc or cobalt hyaluronate associate for the manufacture of pharmaceutical compositions of antimicrobial activity | |
WO2020159892A1 (en) | Antimicrobial composition with procoagulant, immunomodulatory, and tissue regenerative properties | |
CN102335452A (zh) | 一种功能性敷料的配方与制备方法 | |
WO2017215610A1 (zh) | 一种高效安全的壳聚糖衍生物基消毒液及其制备方法 | |
CN109331219A (zh) | 一种壳聚糖液体敷料 | |
CN111991417A (zh) | 一种具有生理响应性的次氯酸凝胶及其在皮肤创面中的应用 | |
US8568711B2 (en) | Antimicrobial compositions | |
CN116850351A (zh) | 一种具有较强抗菌作用的粘弹剂 | |
CN109200326A (zh) | 用于伤口愈合的敷料及创口贴 | |
Oprea et al. | Why should be removed chronic infected abdominal synthetic meshes? A Review | |
RU2715922C1 (ru) | Способ лечения распространенного перитонита | |
TWI519302B (zh) | 創傷癒合組合物及其用途 | |
RU2810573C2 (ru) | Биоактивный гидрогель на основе хитозана высокой молекулярной массы и способ его экстемпорального получения | |
RU2725244C1 (ru) | Способ лечения пародонтита | |
CN108938559B (zh) | 一种dna凝胶杀菌材料及其制备方法和作为杀菌材料应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |